资讯

Endpoints News18 分钟
Schol­ar Rock names new CEO, adds biotech vet­er­ans in C-suite re­build
As it awaits an FDA approval decision on apitegromab for spinal muscular atrophy, Scholar Rock is reshaping its leadership ...
Endpoints News18 分钟
Bio­haven gets an up to $600M in­vest­ment; Prile­nia, Fer­rer make a deal in Eu­rope
Biohaven's $600M financing deal, Protara's cell therapy data, Pfizer's bladder cancer success, plus news from CG Oncology, ...